Post-treatment renal function deterioration following radiation therapy: implications for SABR in primary renal cell cancer
By
Marthe Sophie Kilian
Laura Anna Fischer
Jona Bensberg
Lisa-Antonia von Diest
Carla Marie Zwerenz
Mahalia Z. Anczykowski
Stephanie Bendrich
Manuel Guhlich
Martin Leu
Leif Hendrik Dröge
Tibor I. Kesztyüs
Annemarie Uhlig
Stefan Rieken
Rami A. El Shafie
June 23, 2026
Clinical Scorecard: Renal Function Decline After Radiation Therapy: Considerations for SABR in Primary Renal Cell Carcinoma
At a Glance
Category Detail
Condition Primary Renal Cell Carcinoma Key Mechanisms Radiation exposure linked to dose-dependent reduction in renal function post-treatment. Target Population Patients undergoing stereotactic ablative radiotherapy (SABR) for primary renal cell carcinoma. Care Setting Tertiary university cancer facility
Key Highlights
46.98% of patients experienced deterioration of chronic kidney disease (CKD) post-treatment. Increased renal dose is an independent predictor of renal function decline. Female gender identified as a risk factor for renal function decline. Established thresholds for renal dose: 18.7 Gy (mean) and 19.0 Gy (max). Nephron-sparing SABR is a secure therapeutic approach for primary renal cell carcinoma. Guideline-Based Recommendations
Diagnosis
Evaluate renal function using Common Terminology Criteria for Adverse Events (CTCAE) grading. Management
Consider nephron-sparing SABR for patients with primary renal cell carcinoma. Monitoring & Follow-up
Ongoing renal function monitoring post-treatment is essential. Risks
Increased renal dose correlates with a higher risk of chronic kidney disease progression. Patient & Prescribing Data
Patients with incidental kidney exposure during trunk radiotherapy.
Radiation exposure in low-to-moderate dose ranges linked to renal function decline.
Clinical Best Practices
Refine risk-adapted dose constraints to minimize late tissue damage. Utilize multivariable analyses to assess dose-response relationships. Related Resources & Content
